defeatHIV Collaboratory, Seattle, WA, USA.
School of Medicine, Division of Allergy and Infectious Diseases, Mountain West AIDS Education & Training Center, University of Washington, Seattle, WA, USA.
HIV Res Clin Pract. 2022 Jul 18;23(1):61-75.
Research on stakeholder perspectives of HIV cure research has involved people with HIV (PWH), who generally cite the importance of HIV clinician advice in making decisions about trial participation. However, there has been little exploration of non-researcher community HIV clinician perspectives, which are clearly critical to the success of HIV cure-related research. We aimed to learn how community HIV clinicians perceive HIV cure research and identify factors that would lead them to support or discourage HIV cure trial participation by their patients. We recruited a purposive sample of 12 community HIV clinicians in metro-Seattle, WA to participate in structured interviews. We completed 11 interviews via teleconference and received one written response. We used conventional content analysis to analyze the data. Overall, community HIV clinicians were supportive of patient participation in HIV cure trials. Factors affecting support included knowledge of local trials, ease of referral, patient immune function and health stability, study risks and benefits, burden of study requirements, patient characteristics, patient life stability, potential impact on engagement in care, study communication plans, and beliefs that patients should have the autonomy to decide to participate. Participants had concerns about trials requiring treatment delays or interruptions and HIV transmission risk. While their knowledge of the field was limited, they were interested in learning more about open HIV cure trials. It would benefit the HIV cure research community if those leading HIV cure trials make stronger efforts to engage community clinicians who care for PWH, but are not active researchers, early in the trial design process. Such engagement prior to launching HIV cure trials will improve trial designs, leading to better enrollment and retention within these important studies.
对 HIV 治愈研究中利益相关者观点的研究涉及到 HIV 感染者(PWH),他们普遍认为在决定参与试验时,HIV 临床医生的建议很重要。然而,对于非研究性社区 HIV 临床医生的观点,几乎没有进行过探索,而这些观点对于 HIV 治愈相关研究的成功显然至关重要。我们旨在了解社区 HIV 临床医生如何看待 HIV 治愈研究,并确定哪些因素会导致他们支持或劝阻患者参与 HIV 治愈试验。我们在西雅图都会区招募了 12 名社区 HIV 临床医生作为研究对象,邀请他们参加结构式访谈。我们通过电话会议完成了 11 次访谈,并收到了一份书面回复。我们使用常规内容分析法对数据进行了分析。总体而言,社区 HIV 临床医生支持患者参与 HIV 治愈试验。影响支持的因素包括对当地试验的了解、转介的便利性、患者的免疫功能和健康稳定性、研究的风险和益处、研究要求的负担、患者特征、患者生活的稳定性、对参与护理的潜在影响、研究沟通计划以及患者应该自主决定参与的信念。参与者对需要延迟或中断治疗以及 HIV 传播风险的试验表示担忧。尽管他们对该领域的了解有限,但他们有兴趣更多地了解开放的 HIV 治愈试验。如果那些领导 HIV 治愈试验的人能够更早地努力让关心 HIV 感染者但不是活跃研究人员的社区临床医生参与进来,这将使 HIV 治愈研究界受益。在开展 HIV 治愈试验之前,这种参与将改进试验设计,从而在这些重要研究中更好地招募和保留参与者。